Knight Therapeutics (TSX:GUD) Interest Expense : C$-12.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Knight Therapeutics's interest expense for the three months ended in Mar. 2024 was C$ -2.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was C$-12.3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Knight Therapeutics's Operating Income for the three months ended in Mar. 2024 was C$ 2.7 Mil. Knight Therapeutics's Interest Expense for the three months ended in Mar. 2024 was C$ -2.6 Mil. Knight Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 was 1.03. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Knight Therapeutics Interest Expense Historical Data

The historical data trend for Knight Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Interest Expense Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.37

-3.40

-3.62

-6.60

-12.49

Knight Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-2.79	-3.00	-2.60	-4.09	-2.58

Knight Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-12.3 Mil.

Knight Therapeutics (TSX:GUD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Knight Therapeutics's Interest Expense for the three months ended in Mar. 2024 was C$-2.6 Mil. Its Operating Income for the three months ended in Mar. 2024 was C$2.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was C$48.0 Mil.

Knight Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	2.66	/	-2.577
	=	1.03

The higher the ratio, the stronger the company's financial strength is.

Knight Therapeutics (TSX:GUD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Executives

Sime Armoyan

10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines